SCHEDULE: Rubric Capital Reduces Trevi Therapeutics Stake to 2.94%
Beneficial Ownership Report Amendment
Rubric Capital Management LP and David Rosen have reported a reduced beneficial ownership stake of 2.94% in Trevi Therapeutics, Inc. as of December 31, 2025.
Summary
- Rubric Capital Management LP and David Rosen, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Trevi Therapeutics, Inc.
- As of December 31, 2025, the Reporting Persons beneficially own 3,766,749 shares of Trevi Therapeutics, Inc. Common Stock.
- This ownership represents 2.94% of the outstanding Common Stock, based on 128,230,134 shares outstanding as of October 31, 2025.
- The filing indicates a passive investment, with the securities acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While a reduction in stake could be seen as slightly negative, it's a passive investment below the 5% threshold, suggesting routine portfolio management rather than a strong negative signal about the issuer.
Positives
- NA
Negatives
- The reporting persons have reduced their stake to below the 5% threshold, which could be interpreted as a decrease in conviction or a portfolio rebalancing.
Risks
- NA
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance from Trevi Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.
Management Comments
- NA
Industry Context
StockSavvy.ai notes that a reduction in an institutional investor's stake below the 5% threshold, as reported in this Schedule 13G, typically indicates a passive portfolio adjustment rather than a strategic move to influence the company. For a biotechnology company like Trevi Therapeutics, such a change in ownership by a fund like Rubric Capital Management LP is common as funds rebalance their portfolios based on market conditions, investment theses, or risk management, and does not inherently signal a change in the company's operational trajectory or industry standing.
Comparison to Industry Standards
- This filing primarily concerns a change in beneficial ownership by an institutional investor and does not provide company-specific performance metrics that can be directly compared to industry standards or specific competitor results. The reported 2.94% stake is below the typical 5% threshold that often triggers more active investor engagement or scrutiny in the biotech sector, where significant institutional backing can be a key indicator of confidence.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The reduction in Rubric Capital's stake to below 5% may lead to minor shifts in institutional ownership structure, but is unlikely to significantly impact shareholder sentiment given its passive nature.
- Management: No direct impact on management or operations is indicated by this passive ownership disclosure.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date as of which 128,230,134 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-12-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2026-02-13 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Trevi Therapeutics, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.